Compare
Skinvisible, Inc. vs Talphera, Inc. vs Impact Biomedical Inc. vs Lyell Immunopharma, Inc.
| Latest fiscal year | Skinvisible, Inc. SKVI | Talphera, Inc. TLPH | Impact Biomedical Inc. IBO | Lyell Immunopharma, Inc. LYEL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $20.0K | $28.0K | $32.0K | $36.0K |
| Revenue growth (YoY) | 0.0% | n/a | n/a | -41.0% |
| Gross margin | 100.0% | n/a | n/m (computed) | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$1.06M | -$14.29M | -$11.84M | -$274.45M |
| EPS (Diluted) | n/a | n/a | -$0.38 | -$16.06 |
| Operating cash flow | -$38.4K | -$11.36M | -$1.89M | -$150.02M |
| Free cash flow | -$42.5K | n/a | n/a | -$150.80M |
| Cash & equivalents | n/a | $5.89M | $3.0K | $60.18M |
| Total assets | $127.6K | $29.72M | $17.41M | $340.05M |
| Total liabilities | $10.39M | $12.68M | $1.85M | $91.85M |
| Shareholders' equity | -$10.26M | $17.04M | $12.61M | $248.20M |
| Return on year-end equity | n/a | -83.9% | -93.9% | -110.6% |
| Shares outstanding | 5.40M | 49.33M | 104.62M | 21.25M |
Revenue, most recent five fiscal years
| Fiscal year | Skinvisible, Inc. | Talphera, Inc. | Impact Biomedical Inc. | Lyell Immunopharma, Inc. |
|---|---|---|---|---|
| Latest | $20.0K Ended 2025-12-31 | $28.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $36.0K Ended 2025-12-31 |
| 1 year earlier | $20.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | n/a | $61.0K Ended 2024-12-31 |
| 2 years earlier | $20.0K Ended 2023-12-31 | $651.0K Ended 2023-12-31 | n/a | $130.0K Ended 2023-12-31 |
| 3 years earlier | $279.3K Ended 2022-12-31 | $0 Ended 2022-12-31 | $50.0K Ended 2022-12-31 | $84.68M Ended 2022-12-31 |
| 4 years earlier | $663.4K Ended 2021-12-31 | $2.82M Ended 2021-12-31 | n/a | $10.65M Ended 2021-12-31 |